Biotherapeutics, Inc.

Biotherapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in Blacksburg, Virginia, develops oral first-in-class small-molecule immunoregulatory and immunometabolic therapeutics for inflammatory and autoimmune diseases, funded entirely through federal grants as a prime recipient with no contracts in the source portfolio. The company combines advanced computational modeling with translational experimentation to accelerate development of precision medicine products targeting unmet clinical needs across multiple therapeutic areas.

Biotherapeutics operates exclusively within the Small Business Innovation Research (SBIR) grant ecosystem, competing in Phase I and Phase II awards across National Institutes of Health (NIH) institutes. All 30 awards in the recent portfolio are prime grants; the company has no subcontract or sub-grant exposure. The grant portfolio spans nine distinct customer agencies within HHS, all NIH institutes, with concentration tightly clustered: the National Institute of Allergy and Infectious Diseases (NIAID) accounts for 11 awards (37% of portfolio); the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart Lung and Blood Institute (NHLBI), and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) each carry 4 awards; and the National Institutes of Health central office 2 awards. These five customer entities represent 87% of all recent awards.

Recent capability work spans six therapeutic programs: oral small-molecule immunometabolic therapeutics for multiple sclerosis ($314,363 NIAID Phase I SBIR, September 2026, pharmacokinetic and toxicity validation in rats); novel immunoregulatory therapeutics for Helicobacter pylori-induced bacterial gastritis ($314,363 NIAID Phase I SBIR, August 2026, inflammation-targeted approach to host-centered therapy); next-generation oral therapeutics for concomitant Clostridioides difficile infection and inflammatory bowel disease (NIDDK Phase I SBIR, August 2025, antibiotic-sparing efficacy comparative trials); novel oral therapeutics for systemic lupus erythematosus (NIAID SBIR Fast-Track Phase I/II, August 2025, targeting regulatory CD4+ T cells and myeloid cell tolerance); next-generation oral therapeutics for type 2 diabetes ($314,363 NIDDK Phase I SBIR, July 2025, precision medicine targeting lipid metabolism and insulin sensitivity); and first-in-class topical immunoregulatory therapeutics for asthma and psoriasis (NHLBI and NIAMS Phase I awards, February through September 2024, regulatory T cell manipulation and inflammation suppression). Work is performed in Blacksburg, Virginia.

Activity has declined year over year — four awards in 2021 to two in 2026 — with only three awards reaching ultimate completion within the next twenty-four months, indicating minimal recompete exposure in the near term. The grant portfolio carries a combined obligated value of $19.7 million across all 30 awards. Biotherapeutics competes in full-and-open SBIR solicitations; the company holds no set-aside designations or parent vehicles (IDIQs, GWACs, BPAs) in the source portfolio.